245 related articles for article (PubMed ID: 27236925)
1. Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics.
Nutho B; Meeprasert A; Chulapa M; Kungwan N; Rungrotmongkol T
J Biomol Struct Dyn; 2017 Jun; 35(8):1743-1757. PubMed ID: 27236925
[TBL] [Abstract][Full Text] [Related]
2. Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics.
Zhang HX; Li Y; Wang X; Xiao ZT; Wang YH
Curr Med Chem; 2011; 18(26):4019-28. PubMed ID: 21824089
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598.
Xue W; Jiao P; Liu H; Yao X
Antiviral Res; 2014 Apr; 104():40-51. PubMed ID: 24462692
[TBL] [Abstract][Full Text] [Related]
4. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors.
Yu H; Fang Y; Lu X; Liu Y; Zhang H
Chem Biol Drug Des; 2014 Jan; 83(1):89-105. PubMed ID: 23941500
[TBL] [Abstract][Full Text] [Related]
5. In silico screening for potent inhibitors against the NS3/4A protease of hepatitis C virus.
Meeprasert A; Rungrotmongkol T; Li MS; Hannongbua S
Curr Pharm Des; 2014; 20(21):3465-77. PubMed ID: 24001230
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors.
Das D; Hong J; Chen SH; Wang G; Beigelman L; Seiwert SD; Buckman BO
Bioorg Med Chem; 2011 Aug; 19(16):4690-703. PubMed ID: 21798747
[TBL] [Abstract][Full Text] [Related]
7. Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors.
Hendricks RT; Fell JB; Blake JF; Fischer JP; Robinson JE; Spencer SR; Stengel PJ; Bernacki AL; Leveque VJ; Le Pogam S; Rajyaguru S; Najera I; Josey JA; Harris JR; Swallow S
Bioorg Med Chem Lett; 2009 Jul; 19(13):3637-41. PubMed ID: 19447623
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel natural flavonoids as potent antiviral candidates against hepatitis C virus NS5B polymerase.
Akher FB; Farrokhzadeh A; Ramharack P; Shunmugam L; Van Heerden FR; Soliman MES
Med Hypotheses; 2019 Nov; 132():109359. PubMed ID: 31466018
[TBL] [Abstract][Full Text] [Related]
9. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
Elhefnawi M; ElGamacy M; Fares M
BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
[TBL] [Abstract][Full Text] [Related]
10. Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors.
Therese PJ; Manvar D; Kondepudi S; Battu MB; Sriram D; Basu A; Yogeeswari P; Kaushik-Basu N
J Chem Inf Model; 2014 Feb; 54(2):539-52. PubMed ID: 24460140
[TBL] [Abstract][Full Text] [Related]
11. In silico identification of novel SARS-COV-2 2'-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches.
El Hassab MA; Ibrahim TM; Al-Rashood ST; Alharbi A; Eskandrani RO; Eldehna WM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):727-736. PubMed ID: 33685335
[TBL] [Abstract][Full Text] [Related]
12. Novel Guanosine Derivatives as Anti-HCV NS5b Polymerase: A QSAR and Molecular Docking Study.
Elfiky AA
Med Chem; 2019; 15(2):130-137. PubMed ID: 30324891
[TBL] [Abstract][Full Text] [Related]
13. Comparative Molecular Field Analysis and Molecular Docking Studies on Quinolinone Derivatives Indicate Potential Hepatitis C Virus Inhibitors.
Malathi K; Ramaiah S; Anbarasu A
Cell Biochem Biophys; 2019 Jun; 77(2):139-156. PubMed ID: 30796723
[TBL] [Abstract][Full Text] [Related]
14. Probing the "fingers" domain binding pocket of Hepatitis C virus NS5B RdRp and D559G resistance mutation via molecular docking, molecular dynamics simulation and binding free energy calculations.
Manjula S; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2019 Jun; 37(9):2440-2456. PubMed ID: 30047829
[TBL] [Abstract][Full Text] [Related]
15. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.
Bessa LM; Launay H; Dujardin M; Cantrelle FX; Lippens G; Landrieu I; Schneider R; Hanoulle X
J Biol Chem; 2017 Nov; 292(44):18024-18043. PubMed ID: 28912275
[TBL] [Abstract][Full Text] [Related]
16. Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase.
Talele TT; Arora P; Kulkarni SS; Patel MR; Singh S; Chudayeu M; Kaushik-Basu N
Bioorg Med Chem; 2010 Jul; 18(13):4630-8. PubMed ID: 20627595
[TBL] [Abstract][Full Text] [Related]
17. Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase.
Harikishore A; Li E; Lee JJ; Cho NJ; Yoon HS
Mol Divers; 2015 Aug; 19(3):529-39. PubMed ID: 25862642
[TBL] [Abstract][Full Text] [Related]
18. Novel 4-thiazolidinones as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase.
Çakir G; Küçükgüzel İ; Guhamazumder R; Tatar E; Manvar D; Basu A; Patel BA; Zia J; Talele TT; Kaushik-Basu N
Arch Pharm (Weinheim); 2015 Jan; 348(1):10-22. PubMed ID: 25449674
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel Hepatitis C virus inhibitor targeting multiple allosteric sites of NS5B polymerase.
Khalid H; Landry KB; Ijaz B; Ashfaq UA; Ahmed M; Kanwal A; Froeyen M; Mirza MU
Infect Genet Evol; 2020 Oct; 84():104371. PubMed ID: 32485331
[TBL] [Abstract][Full Text] [Related]
20. Screening and molecular docking of selected phytochemicals against NS5B polymerase of hepatitis c virus.
Mustafa G; Majid M; Ghaffar A; Yameen M; Samad HA; Mahrosh HS
Pak J Pharm Sci; 2020 Sep; 33(5(Supplementary)):2317-2322. PubMed ID: 33832906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
